Related Experiment Videos
Clinical pharmacokinetics of rocuronium bromide
1Department of Anaesthesia and Intensive Care Medicine, Leopold-Franzens-University of Innsbruck, Austria.
Clinical Pharmacokinetics
|September 1, 1996
Summary
Rocuronium bromide, a new aminosteroidal neuromuscular blocking agent, offers rapid tracheal intubation and fewer active metabolites. Its pharmacokinetics are crucial for anesthesiologists to understand its clinical effects and duration.
Area of Science:
- Pharmacology
- Anesthesiology
Background:
- Rocuronium bromide is a new aminosteroidal neuromuscular blocking agent.
- It offers advantages like fast onset for tracheal intubation and reduced active metabolites compared to vecuronium bromide.
Purpose of the Study:
- To review available pharmacokinetic data for rocuronium bromide.
- To discuss the clinical significance of these pharmacokinetic properties for anesthesiologists.
Main Methods:
- Literature review of pharmacokinetic studies on rocuronium bromide.
- Analysis of drug absorption, distribution, metabolism, and excretion.
Main Results:
- Rocuronium bromide has a fast onset of action, beneficial for tracheal intubation.
- It produces fewer active metabolites than vecuronium bromide.
- Hepatic and renal disease have a lesser impact on rocuronium bromide clearance compared to pancuronium or vecuronium.
- Elderly or hypothermic patients may experience a prolonged duration of action due to reduced plasma clearance.
Conclusions:
- Understanding rocuronium bromide's pharmacokinetics is essential for safe and effective clinical use.
- Its pharmacokinetic profile suggests it may be a preferred agent for rapid sequence induction.
- Dosage adjustments may be necessary in elderly or hypothermic patients.